Groundbreaking New Treatment Could Change Migraine Sufferers' Lives Forever

Migraines affect millions of Americans. Although many medications can treat migraines once they occur, there has yet to be to be an effective FDA-approved medication that actually prevents the onset of migraines.

On May 17th, the first medication designed to prevent migraines was approved by the Food and Drug Administration. Four more preventative migraine medications are currently in the pipeline.



The drug is called Aimovig and is a monthly injection, similar to an insulin pen or a vivitrol (opioid blocker) shot.  The medication will cost $6,900 a year—a relatively costly medication. The price tag calls into question the ethics surrounding an absorbent price tag for a medication designed to alleviate the suffering of millions of people.

The drug manufacturers, Amgen and Novartis, promised that the drug would be available this summer. The drug works by blocking a protein fragment, CGRP, that instigates and perpetuates migraines. It is now being considered the best option for individuals who sufferers from at least 15 migraines per month and who have no other viable alternatives.

“The drugs will have a huge impact,” said Dr. Amaal Starling, a neurologist and migraine specialist at the Mayo Clinic in Phoenix. “This is really an amazing time for my patient population and for general neurologists treating patients with migraine.”

Approximately 2 percent of the global population is affected by chronic migraines. Symptoms far supersede a simple headache. Common physiological effects of migraines include debilitating nausea and vomiting, difficulty speaking and sensory sensitivity. It is the third most common disease in the world and one of the top ten causes of disability. The new drug could help millions of people regain normal levels of function.

Current treatment for migraines is problematic at best. Those medications come with a slew of side effects including mental fogginess, sedation, weight gain, sexual dysfunction and dry mouth. These side effects are so severe that 85% of patients stop taking the medications within a year.

According to a report by the Institute for Clinical and Economic Review, migraines have a dramatic impact on patients’ lives.

Those who suffer from chronic migraines tend to avoid making commitments or plans, and are less likely to get involved in the workforce. Migraines are often unpredictable—sufferers have no idea when they will occur or how long they will last.

In the report, sufferers indicated that they felt “frustrated, depressed, defeated, isolated” as a result of their chronic condition. Many patients indicated that they felt limited by the stigma surrounding migraines and they often felt isolated from the rest of society. Those patients frequently tried a slew of treatments with very little relief.

While the new medication is extremely promising for so many people, the high cost calls into question the likelihood that all sufferers will be able to afford it. It is unclear whether insurers will pay the high price tag, or that individuals with large deductibles will be able to afford the medication in the first place.

CNN video; Samuel Corum/Getty Images

With the world facing a viral pathogen with no vaccine or proven effective treatment, people are understandably on edge.

Hoping to give people a smile or a laugh, lawyer and fiscally conservative Republican—and Donald Trump adversary—George Conway decided to give folks the set up for an old joke with a new twist.

Keep reading... Show less
Chip Somodevilla/Getty Images

Even the most powerful office on the planet requires a level of humility and a willingness to admit when something goes wrong. President Donald Trump didn't get that memo.

Whether it's on Obama, the "fake news media," traitorous Republicans, the impeachment "hoax," or anything within even the most laborious reach, Trump can always find some person or entity on whom to pass the blame.

Keep reading... Show less
Fox Business

After less than a year on the job and with zero White House press briefings to her name, Stephanie Grisham will step down as White House press secretary, returning to her work with First Lady Melania Trump as her Chief of Staff.

Stephanie Grisham is the third White House Press Secretary to step down during the administration of President Donald Trump.

Keep reading... Show less
Shannon Finney/Getty Images

Across the country, states have instituted stay-at-home orders in an effort to curb the spread of the highly contagious virus that's upended daily life in the United States.

Late last month, Wisconsin Governor Tony Evers issued one of these orders, urging his constituents to only leave their houses for necessary errands, such as getting groceries or filling prescriptions.

There's just one problem: Wisconsin's elections are scheduled for April 7. In addition to the Presidential primaries, Wisconsinites will vote for judicial positions, school board seats, and thousands of other offices.

The Democratic and Republican National Committees took the case to the Supreme Court, with Democrats arguing that the deadline for mailing absentee ballots should be extended by a week, to April 13, in order to facilitate voting from home.

With a Wisconsin Supreme Court Seat up for grabs on Tuesday, Republicans predictably made the case for why as few people as possible should be permitted to vote. It was a continuation of Wisconsin GOP efforts to suppress the vote, which included rejecting a demand from Governor Evers to automatically mail an absentee ballot to every resident.

The Republican majority in United States Supreme Court sided with the RNC and the election in Wisconsin will carry on as scheduled. This is despite Wisconsin being unprepared for the surge in absentee ballot requests, which leapt from a typical 250,000 to over 1.2 million in reaction to the virus. Thousands of these voters won't even receive these ballots until after the election, thereby preventing them from exercising their right to vote.

Justice Ruth Bader Ginsburg wrote a blistering dissent to the majority's decision, saying:

"Either [voters] will have to brave the polls, endangering their own and others' safety. Or they will lose their right to vote, through no fault of their own. That is a matter of utmost importance — to the constitutional rights of Wisconsin's citizens, the integrity of the State's election process, and in this most extraordinary time, the health of the Nation."

She was flabbergasted that her more conservative colleagues didn't think a global pandemic and national crisis was enough to justify emergency policies ensuring Wisconsinites their right to vote:

"The Court's suggestion that the current situation is not 'substantially different' from 'an ordinary
election' boggles the mind...Now, under this Court's order, tens of thousands of absentee voters, unlikely to receive their ballots in time to cast them, will be left quite literally without a vote."

A majority of the Supreme Court may not have agreed with Ginsburg, but the court of public opinion was fully on her side.

The Republican efforts indicated to some that the party cares more about maintaining control than preserving lives.

Large crowds are already gathering in Wisconsin to vote.

In a bit of devastating irony, the Supreme Court voted remotely when making its decision.

For more information about the tried and true tactic of GOP voter suppression, check out Uncounted, available here.

JIM WATSON/AFP via Getty Images

Despite numerous cautions from medical experts—including those on his staff—President Donald Trump continues to tout hydroxychloroquine as a promising treatment for the virus that's brought daily life in the United States to a standstill.

The drug has undergone no clinical trials to scientifically test its efficacy on the virus, and the evidence on its behalf is anecdotal at best. One Fox News guest, Access Health International Chairman William Haseltine, called it a "quack cure."

Keep reading... Show less
Catherine Nance / Echoes Wire/Barcroft Media via Getty Images

President Donald Trump's personal lawyer, Rudy Giuliani, is back in the public eye after keeping a relatively low profile following the impeachment trial against his client.

Keep reading... Show less